EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel TIRAP-MyD88 inhibitor blocks TLR7- and TLR8-induced type I IFN responses

Kaja Elisabeth Nilsen, Jørgen Stenvik, Astrid Skjesol, Ingvild Bergdal Mestvedt, Siril Skaret Bakke, Miriam Soledad Giambelluca, Caroline S Gravastrand, Kirusika Elamurugan, Liv Ryan, Terje Espevik, Maria Yurchenko

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Kaja Elisabeth Nilsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Toll-Like Receptor 7, Toll-Like Receptor 8, Receptors, Interleukin-1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway through its Centers of Excellence Funding Scheme, NTNU Discovery Grant 2020 (to T.E. and M.Y.), Liaison Committee for Education, Research and Innovation in Central Norway Innovation Researcher.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endosomal toll-like receptors TLR7 and TLR8 are critical sensors of microbial RNA that initiate antiviral and antibacterial immune responses through type I interferon (IFN) and proinflammatory cytokine production. While TIRAP is traditionally associated with plasma membrane TLR signaling, recent evidence suggests that it also contributes to signaling via endosomal TLRs. Here, we examined the role of TIRAP in TLR7/8 signaling using P7-Pen, a novel SLAMF1-derived peptide that disrupts the TIRAP–MyD88 interaction. In primary human monocytes and a whole blood model, P7-Pen inhibited TLR7- and TLR8-induced expression and secretion of IRF5-regulated cytokines IFNβ, IL-12p40, and IL-12p70, without effect on TNF or IL-6. Mechanistically, P7-Pen blocked TIRAP recruitment to the TLR8-MyD88 complex, leading to reduced late-stage IRAK1 activation, Akt and IKKα/β phosphorylation, and downstream IRF5 dimerization and nuclear translocation. Inhibition of Staphylococcus aureus–induced cytokine production by P7-Pen was associated with reduced bacterial phagocytosis, impairing endosomal delivery of bacterial RNA. Notably, P7-Pen failed to inhibit murine TLR7 responses, which correlated with a lack of TIRAP recruitment to MyD88 in mouse macrophages following TLR7 ligand stimulation, highlighting species-specific differences in TLR signaling mechanisms. These findings support a noncanonical role for TIRAP in regulating IRF5-dependent signaling downstream of human TLR7 and TLR8, and demonstrate that selective disruption of TIRAP recruitment by a SLAMF1-derived peptide effectively attenuates IFNβ production. This strategy may hold therapeutic potential in diseases characterized by dysregulated type I IFN responses, such as systemic lupus erythematosus and chronic infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Differentiation Factor 88Toll-Like Receptor 7Toll-Like Receptor 8Receptors, Interleukin-1Membrane GlycoproteinsInterferon Type IHumansAnimalsMiceSignal TransductionMice, Inbred C57BLMice, KnockoutMonocytes

Stichwörter der Autor:innen

IFNβTIRAPTLR8macrophagespeptide

Substanzen

Myeloid Differentiation Factor 88Toll-Like Receptor 7Toll-Like Receptor 8Receptors, Interleukin-1TIRAP protein, humanMembrane GlycoproteinsInterferon Type ITLR7 protein, humanTLR8 protein, humanTIRAP protein, mouse

Autor:innen und Institutionen

  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Infectious Diseases, Clinic of Medicine, St. Olavs Hospital HF, Trondheim University Hospital, Trondheim, Norway.

Förderung

  • Research Council of Norway through its Centers of Excellence Funding Scheme
  • NTNU Discovery Grant 2020 (to T.E. and M.Y.)
  • Liaison Committee for Education, Research and Innovation in Central Norway Innovation Researcher
  • Felles Forskningsutvalg
  • NTNU Discovery

Zitieren

APA

Nilsen, K. E., Stenvik, J., Skjesol, A., Mestvedt, I. B., Bakke, S. S., Giambelluca, M. S., Gravastrand, C. S., Elamurugan, K., Ryan, L., Espevik, T., & Yurchenko, M. (2025). A novel TIRAP-MyD88 inhibitor blocks TLR7- and TLR8-induced type I IFN responses. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf258

Vancouver

Nilsen KE, Stenvik J, Skjesol A, Mestvedt IB, Bakke SS, Giambelluca MS, et al. A novel TIRAP-MyD88 inhibitor blocks TLR7- and TLR8-induced type I IFN responses. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf258

BibTeX
@article{Nilsen2025,
  author = {Nilsen, Kaja Elisabeth and Stenvik, Jørgen and Skjesol, Astrid and Mestvedt, Ingvild Bergdal and Bakke, Siril Skaret and Giambelluca, Miriam Soledad and Gravastrand, Caroline S and Elamurugan, Kirusika and Ryan, Liv and Espevik, Terje and Yurchenko, Maria},
  title = {A novel TIRAP-MyD88 inhibitor blocks TLR7- and TLR8-induced type I IFN responses},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf258}
}
Kostenlos starten →